Core Viewpoint - Alexandria Real Estate Equities, Inc. has announced the pricing of a public offering of $750 million in senior notes due 2036, with a yield to maturity of 5.291% [1] Group 1: Offering Details - The company priced the senior notes at 99.679% of the principal amount [1] - The notes will be unsecured obligations of the company and fully guaranteed by Alexandria Real Estate Equities, L.P., a wholly owned subsidiary [1] - The closing of the sale is expected to occur on or about February 25, 2026, subject to customary closing conditions [1] Group 2: Use of Proceeds - The net proceeds from the notes are expected to be used to repay a portion of borrowings under the company's commercial paper program, specifically for the repurchase or redemption of approximately $952.2 million of certain series of outstanding senior unsecured notes [1] - Pending the use of proceeds, the company may invest in high-quality short-term securities or use the funds for general working capital and corporate purposes [1] Group 3: Underwriting and Management - Citigroup Global Markets Inc., BofA Securities, Inc., J.P. Morgan Securities LLC, and several other firms are acting as joint book-running managers for the public offering [1] - Additional firms, including Barclays Capital Inc. and Capital One Securities, Inc., are serving as co-managers for the offering [1] Group 4: Company Background - Alexandria Real Estate Equities, Inc. is a leading life science REIT, founded in 1994, and is recognized for its role in developing collaborative ecosystems in major life science innovation clusters [1]

Core Viewpoint - Dakota Gold Corp. has announced a public offering of 12,336,000 shares of its common stock, aiming to raise approximately $75 million, which could increase to about $86.25 million if the underwriters fully exercise their option [1][2]. Group 1: Offering Details - The public offering is expected to close on or about February 11, 2026, pending customary closing conditions [1]. - The gross proceeds from the offering, before expenses, are estimated at approximately $75 million, with a potential increase to $86.25 million if the underwriters exercise their option in full [2]. - The net proceeds from the offering will be utilized for working capital and other general corporate purposes [2]. Group 2: Underwriters and Options - BMO Capital Markets and Scotiabank are acting as lead book-running managers for the offering, with several other firms serving as co-managers [3]. - The underwriters have been granted an option to purchase an additional 1,850,400 shares, representing up to 15% of the shares being sold in the offering, exercisable for 30 days from the underwriting agreement date [4]. Group 3: Regulatory Compliance - The offering is being conducted under the company's effective shelf registration statement on Form S-3, which includes a base prospectus previously filed with the SEC [5].

Core Viewpoint - Lexicon Pharmaceuticals has successfully closed a public offering of 32 million shares of common stock and a concurrent private placement of 22.4 million shares of common stock and 367,145 shares of Series B Convertible Preferred Stock, with the offerings closing on February 2, 2026 [1]. Group 1: Offering Details - The public offering price for the common stock was set at $1.30 per share, while the Series B Convertible Preferred Stock was sold at $65 per share [1]. - An additional 30-day option has been granted to underwriters to purchase up to 4.8 million shares of common stock at the public offering price [2]. - The Private Placement Purchaser has the option to buy an additional 94,855 shares of Series B Convertible Preferred Stock, convertible into 4,742,744 shares of common stock, at the same price of $65 per share [2]. Group 2: Use of Proceeds - Lexicon intends to utilize the net proceeds from the offerings for the continued research and development of its drug candidates, as well as for working capital and other general corporate purposes [4]. Group 3: Regulatory Information - A shelf registration statement related to the public offering was filed with the SEC on August 2, 2024, and was declared effective on August 15, 2024 [5]. - The shares issued in the private placement have not been registered under the Securities Act and may not be offered or sold in the U.S. without proper registration or exemption [5]. Group 4: Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing medicines that transform patients' lives, with a pipeline targeting neuropathic pain, hypertrophic cardiomyopathy, obesity, metabolism, and other indications [7].

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE: DSS) (the “Company”), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $1.0 million, before deducting underwriting fees and other offering expenses payable by the Company. The offering consist ...

Core Viewpoint - nLIGHT, Inc. has announced a public offering of 3,977,273 shares of common stock at a price of $44.00 per share, aiming to raise approximately $175 million in gross proceeds before expenses [1]. Company Overview - nLIGHT, Inc. is a leading provider of high-power lasers for mission-critical directed energy, optical sensing, and advanced manufacturing applications [6]. - The company is headquartered in Camas, Washington, and employs around 800 people with operations in the United States, Europe, and Asia [6]. Offering Details - The public offering is priced at $44.00 per share, with an option for underwriters to purchase an additional 596,590 shares [1]. - The net proceeds from the offering will be used for working capital, capital expenditures, and other general corporate purposes [1]. - The offering is expected to close on February 5, 2026, subject to market conditions [1]. Underwriters - Stifel, Baird, William Blair, and Raymond James are acting as joint lead book-running managers for the offering [2]. - Cantor is the book-running manager, while Needham & Company is acting as co-manager [2]. Regulatory Information - An automatically effective shelf registration statement on Form S-3 was filed with the SEC on February 3, 2026, relating to the securities offered [3]. - The offering is being made only by means of a preliminary prospectus supplement and the accompanying base prospectus [3].

Group 1 - DSS, Inc. has commenced a public offering to sell shares of its Common Stock, with all shares being offered by the Company [1] - The net proceeds from the Offering will be used for general corporate and working capital needs [2] - Aegis Capital Corp. is acting as the sole book-running manager for the offering on a firm commitment basis [3] Group 2 - The offering is made pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission (SEC) [3] - A final prospectus supplement and accompanying prospectus will be filed with the SEC and will be available on the SEC's website [3] - DSS, Inc. operates across multiple business lines including health and wellness, packaging, real estate, and securities and blockchain [5]

Core Viewpoint - Elong Power Holding Limited has successfully closed a public offering of 2,400,000 Units at a price of US$3.16 per Unit, raising approximately US$7.6 million for general corporate purposes and working capital [1][4]. Group 1: Offering Details - Each Unit in the offering consists of one Class A ordinary share and one Common Warrant to purchase an additional Class A ordinary share [1]. - The Common Warrants are exercisable immediately at an exercise price of US$3.16 per share, with adjustments to 70% and 50% of the initial price on specified dates [2]. - The underwriter has a 45-day option to purchase up to 360,000 additional Class A ordinary shares and/or Common Warrants to cover over-allotments, with partial exercise already executed for 242,270 Common Warrants [3]. Group 2: Financial Proceeds and Use - The total gross proceeds from the offering amount to approximately US$7.6 million before deducting underwriting discounts and expenses [4]. - The proceeds will be utilized for general corporate purposes and working capital [4]. Group 3: Company Overview - Elong Power is focused on the research, development, manufacturing, sales, and service of high-power lithium-ion batteries for electric vehicles and energy storage systems [7]. - The company has a comprehensive product and technology system that includes battery cells, modules, and battery management systems, catering to high-power applications and energy storage needs [8].

The joint book-running managers for the offering are Keefe, Bruyette & Woods, Inc., A Stifel Company, B. Riley Securities, Inc., Lucid Capital Markets, LLC and Oppenheimer & Co. Inc. Investors are advised to carefully consider the investment objective, risks, charges and expenses of the Company before investing. The preliminary prospectus supplement dated February 2, 2026 and the accompanying base prospectus dated June 18, 2024, which have been filed with the Securities and Exchange Commission ("SEC†), co ...

Core Viewpoint - Elong Power Holding Limited has announced a public offering of 2,400,000 Units at a price of US$3.16 per Unit, aiming to raise approximately US$7.6 million for various corporate purposes [1][3]. Group 1: Offering Details - The offering consists of Units that include one Class A ordinary share or a pre-funded warrant to purchase one Class A ordinary share, along with a common warrant to purchase one Class A ordinary share [1]. - Each common warrant will expire three years from issuance and is exercisable immediately at an exercise price of US$3.16 per share, with potential adjustments to the exercise price [2]. - The offering is expected to close on February 3, 2026, subject to customary closing conditions [3]. Group 2: Use of Proceeds - The proceeds from the offering will be allocated for general corporate purposes and working capital [3]. - Funds will also be used for expanding the sales network, including hiring sales personnel and developing regional sales channels [3]. - Additionally, the company plans to invest in production and capacity expansion, including new equipment and upgrades to manufacturing facilities [3]. Group 3: Underwriting and Legal Aspects - The underwriters have a 45-day option to purchase up to an additional 360,000 Class A ordinary shares and/or common warrants at the public offering price [4]. - Maxin Group LLC is the exclusive underwriter, while Ortoli Rosenstadt LLP and Pryor Cashman LLP are acting as U.S. securities counsel for the company and the underwriter, respectively [4]. Group 4: Company Overview - Elong Power is focused on the research, development, manufacturing, sales, and service of high-power lithium-ion batteries for electric vehicles and energy storage systems [7]. - The company has a comprehensive product and technology system that includes battery cells, modules, system integration, and battery management system development [8]. - Elong Power's product portfolio includes lithium manganese oxide and lithium iron phosphate batteries, catering to high-power and energy storage applications [8].

Wuxi, China, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) (the “Company”) today announced the closing of a best-efforts follow-on public offering of 21,875,000 units (each a “Unit”) at an offering price of US$0.112 per Unit. Each Unit consists of one Class A ordinary share of the Company, par value US$0.00002 per share (each, a “Class A Ordinary Share”) and one warrant to purchase one Class A Ordinary Share, or up to nine Class A Ordinary Shares pursuant to the al ...